Literature DB >> 1560408

Nasal administration of naloxone for detection of opiate dependence.

N Loimer1, P Hofmann, H R Chaudhry.   

Abstract

In clinical trials, nasally applied naloxone was used to identify opiate dependence in humans for the first time. Withdrawal distress was recorded, and pupillary response, pulse rate and blood pressure measured. A significant increase in withdrawal distress and pupillary dilation was observed after nasal administration of 1mg (1mg/400 microliters) naloxone in all subjects who also showed opiate-positive urine samples. In control subjects, no reaction to naloxone was observed. It may be concluded that the nasal route for naloxone administration is as effective as the parenteral route. This test is sensitive enough to identify the physically-dependent opiate user and might have a role in emergency medicine and withdrawal treatment.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1560408     DOI: 10.1016/0022-3956(92)90014-f

Source DB:  PubMed          Journal:  J Psychiatr Res        ISSN: 0022-3956            Impact factor:   4.791


  12 in total

Review 1.  Naloxone dosage for opioid reversal: current evidence and clinical implications.

Authors:  Rachael Rzasa Lynn; J L Galinkin
Journal:  Ther Adv Drug Saf       Date:  2017-12-13

2.  A response to the opioid overdose epidemic: naloxone nasal spray.

Authors:  Daniel P Wermeling
Journal:  Drug Deliv Transl Res       Date:  2013-02-01       Impact factor: 4.617

3.  Expanding access to naloxone in the United States.

Authors:  Suzanne Doyon; Steven E Aks; Scott Schaeffer
Journal:  J Med Toxicol       Date:  2014-12

4.  Pharmacokinetics and -dynamics of intramuscular and intranasal naloxone: an explorative study in healthy volunteers.

Authors:  Arne Kristian Skulberg; Ida Tylleskar; Turid Nilsen; Sissel Skarra; Øyvind Salvesen; Trond Sand; Thorsteinn Loftsson; Ola Dale
Journal:  Eur J Clin Pharmacol       Date:  2018-03-22       Impact factor: 2.953

5.  Pharmacodynamics and arteriovenous difference of intravenous naloxone in healthy volunteers exposed to remifentanil.

Authors:  Ida Tylleskar; Arne Kristian Skulberg; Sissel Skarra; Turid Nilsen; Ola Dale
Journal:  Eur J Clin Pharmacol       Date:  2018-08-24       Impact factor: 2.953

Review 6.  Best evidence topic report. Intranasal naloxone in suspected opioid overdose.

Authors:  Helen Ashton; Ziauddin Hassan
Journal:  Emerg Med J       Date:  2006-03       Impact factor: 2.740

Review 7.  Countermeasures for Preventing and Treating Opioid Overdose.

Authors:  Charles P France; Gerard P Ahern; Saadyah Averick; Alex Disney; Heather A Enright; Babak Esmaeli-Azad; Arianna Federico; Lisa R Gerak; Stephen M Husbands; Benedict Kolber; Edmond Y Lau; Victoria Lao; David R Maguire; Michael A Malfatti; Girardo Martinez; Brian P Mayer; Marco Pravetoni; Niaz Sahibzada; Phil Skolnick; Evan Y Snyder; Nestor Tomycz; Carlos A Valdez; Jim Zapf
Journal:  Clin Pharmacol Ther       Date:  2020-11-29       Impact factor: 6.875

8.  Naloxone therapy in opioid overdose patients: intranasal or intravenous? A randomized clinical trial.

Authors:  Ali Mohammad Sabzghabaee; Nastaran Eizadi-Mood; Ahmad Yaraghi; Samaneh Zandifar
Journal:  Arch Med Sci       Date:  2014-05-13       Impact factor: 3.318

Review 9.  Intranasal naloxone and related strategies for opioid overdose intervention by nonmedical personnel: a review.

Authors:  Christa R Lewis; Hoa T Vo; Marc Fishman
Journal:  Subst Abuse Rehabil       Date:  2017-10-11

10.  A 12-year follow-up of a sample of patients dependent upon heroin.

Authors:  Saima Niaz; Nadia Arshad; Mariam Haroon; Fahd A Cheema; Khalid A Mufti; Haroon Rashid Chaudhry
Journal:  Int Psychiatry       Date:  2007-10-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.